EP4248952A1 — Controlled release 25-hydroxyvitamin d
Assigned to Eirgen Pharma Ltd · Expires 2023-09-27 · 3y expired
What this patent protects
The invention provides a pharmaceutical composition comprising an oral formulation of 25-hydroxyvitamin D 3 for use in a method of treatment of secondary hyperparathyroidism in a human patient having chronic kidney disease. The method of treatment comprises administering the com…
USPTO Abstract
The invention provides a pharmaceutical composition comprising an oral formulation of 25-hydroxyvitamin D 3 for use in a method of treatment of secondary hyperparathyroidism in a human patient having chronic kidney disease. The method of treatment comprises administering the composition to the patient and the patient is treated without causing supraphysiological surges in blood levels of 25-hydroxyvitamin D 3 .
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.